{"transactions":[{"id":869003,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T16:17:09.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":56000,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001193125-26-088251","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000119312526088251/ownership.xml","form_type":"4"}},{"id":869002,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-03T16:17:09.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":39200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":137733,"source":{"system":"sec-edgar","filing":"0001193125-26-088251","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000119312526088251/ownership.xml","form_type":"4"}},{"id":944918,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-07T16:05:16.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":8508,"price":9.21,"value":78358.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 925 and 932 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively."}],"balance_after":98533,"source":{"system":"sec-edgar","filing":"0001193125-26-006292","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000119312526006292/ownership.xml","form_type":"4"}},{"id":1025010,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-03T17:13:56.000Z","date":"2025-10-01","kind":"sale","planned":false,"acquired":false,"shares":31,"price":17.38,"value":538.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":105184,"source":{"system":"sec-edgar","filing":"0001193125-25-230424","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000119312525230424/ownership.xml","form_type":"4"}},{"id":1230244,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T16:24:10.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":53714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":53714,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":53714},"source":{"system":"sec-edgar","filing":"0000950170-25-032101","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000095017025032101/ownership.xml","form_type":"4"}},{"id":1230243,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-04T16:24:10.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":37600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":105215,"source":{"system":"sec-edgar","filing":"0000950170-25-032101","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000095017025032101/ownership.xml","form_type":"4"}}]}